Aclaris Therapeutics to Hold R&D Day
WAYNE, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will host an R&D day for analysts and investors focused on its pipeline of novel drug candidates for immuno-inflammatory diseases on Friday, September 27, 2019 from 8:00 AM to 11:00 AM in New York, New York.
Topics to be covered include:
- KINect Platform: Our Drug Discovery Engine
- ATI-450 (MK2 Inhibitor): An Oral Alternative to Injectable Anti-Cytokine Biologics and JAK Inhibitors for Immuno-Inflammatory Diseases
- ATI-1777: A “Soft” Topical JAK 1/3 Inhibitor
- ATI-2138: An ITK/TXK/JAK3 Inhibitor for Autoimmune Disease
- Gut Restricted Inhibitors of ITK and/or JAK Kinases as Drugs for Inflammatory Bowel Disease
The event will be webcast live over the Internet and can be accessed by logging on to the “Investors” page of the Aclaris Therapeutics website, , prior to the event on the morning of September 27, 2019. A replay of the webcast will be archived on the Aclaris Therapeutics website for 30 days following the call. If you are a member of the investment community and would like to attend, please RSVP to .
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical company committed to addressing the needs of people with immuno-inflammatory diseases who lack satisfactory treatment options. The company’s diverse portfolio includes one late-stage investigational medicine and a pipeline powered by a robust R&D engine exploring protein kinase regulation. Aclaris Therapeutics’ active development programs focus on areas where significant treatment gaps exist. For additional information, please visit and follow Aclaris on LinkedIn or Twitter @aclaristx.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding the development of Aclaris’ drug candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and in commercialization of products, Aclaris’ reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2018, Aclaris Quarterly report on Form 10-Q for the quarter ended June 30, 2019, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC filings” section of the Investors page of Aclaris’ website at . Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Aclaris Contact
Michael Tung, M.D.
Senior Vice President
Corporate Strategy/Investor Relations
484-329-2140
